Case Type: Mergers & Acquisitions

We are investigating Osiris Therapeutics, Inc. (NasdaqGM: OSIR) relating to the sale of the Company to Smith & Nephew plc. Under the transaction, Osiris shareholders will receive $19.00 in cash for each share of Osiris stock they hold.

We are investigating the Board of Directors of Newmont Mining Corporation (NYSE: NEM) related to the Company’s acquisition of Goldcorp Inc. Under the terms of the proposed transaction, Goldcorp shareholders will receive 0.3280 of a share of Newmont common stock and $0.02 in cash for each Goldcorp common share.

We are investigating the Board of Directors of Bemis Company, Inc. (NYSE: BMS) related to the sale of the company to Amcor plc. Under the terms of the proposed transaction, Bemis shareholders will receive 5.1 shares of Amcor plc stock for each share of Bemis stock they own.

We are investigating Spark Therapeutics, Inc. (NasdaqGS: ONCE) relating to the sale of the Company to Roche Holdings, Inc. Under the terms of the agreement, Spark Therapeutics shareholders are only anticipated to receive $114.50 in cash for each share of Spark Therapeutics they own.

We are investigating the Board of Directors of SunCoke Energy Partners, L.P. (NYSE: SXCP) related to the sale of the company to SunCoke Energy, Inc. Under the terms of the proposed transaction, SunCoke Energy Partners stockholders will receive 1.40 shares of SunCoke Energy, Inc. for each share of SunCoke Energy Partners common stock owned.

We are investigating the Board of Directors of Top Image Systems Ltd. (NasdaqCM: TISA) related to the sale of the company to Kofax Holdings International Ltd. Under the terms of the proposed transaction, Top Image stockholders will receive $0.86 in cash for each ordinary share of Top Image.

We are investigating the Board of Directors of Determine, Inc. (Other: DTRM) related to the sale of the company to Corcentric Acquisition, LLC. Under the terms of the proposed transaction, Determine has agreed to sell substantially all of its assets to Corcentric for a cash purchase price of $32,000,000.

We are investigating the Board of Directors of Churchill Capital Corp (NYSE: CCC ) related to the sale of the company to Clarivate Analytics PLC. Under the terms of the proposed transaction, each outstanding share of common stock of Churchill will be converted into one ordinary share of Clarivate.

We are investigating the Board of Directors of Blue Valley Ban Corp. (Other: BVBC) related to the sale of the company to Heartland Financial USA, Inc. Under the terms of the proposed transaction, each share of Blue Valley common stock will receive 0.3271 shares of Heartland common stock.

We are investigating the Board of Directors of Immune Design Corp. (NasdaqGS: IMDZ) regarding its sale to Merck Sharp & Dohme Corp. for $5.85 per each share of Immune Design Corp.